7 Tesla MRI Neuroimaging in Testicular Cancer Patients With Hypogonadism and on Androgen Replacement Therapy
Key facts
- Who runs it
- University of Southern California
- Where
- Los Angeles, United StatesSee the 2 sites
- Trial code
- Status
- Suspended
- People taking part
- 10 people, planned
- Started
- 29 Nov 2022
- Expected to end
- 31 Dec 2027
- Type of study
- Observational
- Treatments tested
- 7 Tesla Magnetic Resonance Imaging
- Biospecimen Collection
- Cognitive Assessment
- Record updated
- 5 June 2026
- Why it stopped
- Study team is conducting interim analysis.
Who can take part
- Age
- 18 years and older
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Males age >= 18 years
- Diagnosed with germ cell tumor of the testis (seminoma or non-seminoma) and treated with radical orchiectomy
- Diagnosed with hypogonadism and started androgen replacement therapy 6 months prior (+/- 2 weeks)
- Ability to understand and the willingness to sign a written informed consent
- Ability to undergo imaging procedure without any form of sedation
Who cannot take part
- History of ART prior to current ART regimen
- Standard contraindications for MRI:; Prior work as a machinist or metal worker, or history of metal being removed from the eyes; Cardiac pacemaker or internal pacing wires; Non-MRI compatible vena cava filter, vascular aneurysm clip, heart valve, spinal or ventricular shunt, optic implant, neuro-stimulator unit, ocular implant, or intrauterine device, or; Claustrophobia, or uncontrollable motion disorder
- History of any neuropsychiatric disease
- History of narcotic use or psychiatric medications
- Current active second malignancy
Where in United States
- Los Angeles General Medical CenterLos Angeles, United States
- USC / Norris Comprehensive Cancer CenterLos Angeles, United States
About the trial
What the trial wants to find out
This study evaluates 7 Tesla (T) magnetic resonance imaging (MRI) in observing changes in the brain (neuroimaging) in testicular cancer patients who have decreased testosterone (hypogonadism) and are on testosterone (androgen) replacement therapy. Symptoms of hypogonadism can include fatigue, weakness, loss of libido, depression, poor concentration and erectile dysfunction. Some patients experience mental changes after diagnosis and treatment. There is some evidence that hypogonadism produces structural changes in the brain. The 7T MRI uses radio waves and a very powerful magnet linked to a computer to create detailed pictures of areas inside the body. This study may help researchers learn if 7T MRI can produce better images to assess the changes in the brain structure of testicular patients with hypogonadism and on androgen replacement therapy (ART).
The group in the trial
- Observational (7T MRI, cognitive assessment, blood collection)
Patients undergo 7T MRI over 1-2 hours at baseline and at 12 months after baseline. Patients also undergo a proctored cognitive assessment over approximately 1 hour prior to each MRI. Additionally, patients undergo blood sample collection at screening and at 12 months after baseline MRI.
Treatment: 7 Tesla Magnetic Resonance Imaging, Biospecimen Collection, and Cognitive Assessment
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Pilot Study of 7 Tesla MRI Neuroimaging in Testicular Cancer Patients With Hypogonadism and Androgen Replacement Therapy
- Record updated
- 5 June 2026